blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1047416

EP1047416 - PHARMACEUTICAL COMPOSITIONS COMPRISING DISULFIRAM FOR INHIBITING ANGIOGENESIS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  29.05.2009
Database last updated on 02.09.2024
Most recent event   Tooltip30.09.2011Lapse of the patent in a contracting state
New state(s): CY		published on 02.11.2011  [2011/44]
Applicant(s)For all designated states
YEDA RESEARCH AND DEVELOPMENT CO., LTD.
The Weizmann Institute of Science P.O. Box 95
76100 Rehovot / IL
[2007/44]
Former [2007/43]For all designated states
YEDA RESEARCH AND DEVELOPMEMT CO., LTD.
The Weizmann Institute of Science P.O. Box 95
76100 Rehovot / IL
Former [2000/44]For all designated states
YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.
Weizmann Institute of Science Herzl Street at Yavne Road P.O. Box 95
Rehovot 76100 / IL
Inventor(s)01 / MARIKOVSKY, Moshe
Shazar Street 9
76804 Mazkeret Batya / IL
[2000/44]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[N/P]
Former [2008/35]Vossius & Partner
Siebertstrasse 3
81675 München / DE
Former [2000/44]VOSSIUS & PARTNER
Siebertstrasse 4
81675 München / DE
Application number, filing date99900280.111.01.1999
[2000/44]
WO1999IL00017
Priority number, dateIL1998012289211.01.1998         Original published format: IL 12289298
[2000/44]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO9934784
Date:15.07.1999
Language:EN
[1999/28]
Type: A2 Application without search report 
No.:EP1047416
Date:02.11.2000
Language:EN
The application published by WIPO in one of the EPO official languages on 15.07.1999 takes the place of the publication of the European patent application.
[2000/44]
Type: B1 Patent specification 
No.:EP1047416
Date:23.07.2008
Language:EN
[2008/30]
Search report(s)International search report - published on:EP08.09.2000
ClassificationIPC:A61K31/27, A61P25/00, A61P27/02, A61P27/06, A61P35/00
[2007/32]
CPC:
A61K31/27 (EP,US); A61P17/00 (EP); A61P17/02 (EP);
A61P19/00 (EP); A61P21/00 (EP); A61P25/00 (EP);
A61P27/02 (EP); A61P27/06 (EP); A61P35/00 (EP);
A61P35/04 (EP); A61P43/00 (EP); A61P9/00 (EP);
A61P9/10 (EP) (-)
Former IPC [2000/44]A61K31/27
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2000/44]
Extension statesAL10.08.2000
LT10.08.2000
LV10.08.2000
MK10.08.2000
RO10.08.2000
SI10.08.2000
TitleGerman:DISULFIRAM ENTHALTENDE ARZNEIMITTEL[2008/19]
English:PHARMACEUTICAL COMPOSITIONS COMPRISING DISULFIRAM FOR INHIBITING ANGIOGENESIS[2000/44]
French:COMPOSITIONS PHARMACEUTIQUES CONTENANT DU DISULFIRAME POUR INHIBER L'ANGIOGENÈSE[2007/32]
Former [2000/44]DISULFIRAM ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN ZUR HEMMUNG DER ANGIOGENESE
Former [2000/44]COMPOSITIONS PHARMACEUTIQUES CONTENANT DU DISULFIRAME
Entry into regional phase10.08.2000National basic fee paid 
10.08.2000Designation fee(s) paid 
10.08.2000Examination fee paid 
Examination procedure01.08.1999Request for preliminary examination filed
International Preliminary Examining Authority: EP
10.08.2000Examination requested  [2000/44]
16.01.2003Despatch of a communication from the examining division (Time limit: M04)
26.05.2003Reply to a communication from the examining division
24.06.2004Despatch of a communication from the examining division (Time limit: M04)
27.10.2004Reply to a communication from the examining division
31.01.2006Despatch of a communication from the examining division (Time limit: M02)
06.04.2006Reply to a communication from the examining division
19.07.2007Cancellation of oral proceeding that was planned for 14.09.2007
19.07.2007Minutes of oral proceedings despatched
13.08.2007Communication of intention to grant the patent
14.09.2007Date of oral proceedings (cancelled)
20.12.2007Fee for grant paid
20.12.2007Fee for publishing/printing paid
Opposition(s)24.04.2009No opposition filed within time limit [2009/27]
Fees paidRenewal fee
11.01.2001Renewal fee patent year 03
14.01.2002Renewal fee patent year 04
14.01.2003Renewal fee patent year 05
14.01.2004Renewal fee patent year 06
12.01.2005Renewal fee patent year 07
12.01.2006Renewal fee patent year 08
12.01.2007Renewal fee patent year 09
14.01.2008Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT23.07.2008
BE23.07.2008
CY23.07.2008
FI23.07.2008
IT23.07.2008
GR24.10.2008
ES03.11.2008
PT23.12.2008
LU11.01.2009
MC31.01.2009
[2011/44]
Former [2011/25]AT23.07.2008
BE23.07.2008
FI23.07.2008
IT23.07.2008
GR24.10.2008
ES03.11.2008
PT23.12.2008
LU11.01.2009
MC31.01.2009
Former [2010/06]AT23.07.2008
BE23.07.2008
FI23.07.2008
IT23.07.2008
ES03.11.2008
PT23.12.2008
MC31.01.2009
Former [2009/19]AT23.07.2008
BE23.07.2008
FI23.07.2008
ES03.11.2008
PT23.12.2008
Former [2009/15]AT23.07.2008
FI23.07.2008
ES03.11.2008
PT23.12.2008
Former [2009/12]FI23.07.2008
ES03.11.2008
PT23.12.2008
Former [2009/09]ES03.11.2008
PT23.12.2008
Cited inInternational search[A]EP0284879  (MERRELL DOW PHARMA [US]) [A] 1-39 * claim - *;
 [D]US4870101  (KU GEORGE [US], et al);
 [X]WO9530415  (UNIV EMORY [US]) [X] 1-13,22-24,32-34 * page 7, lines 17-32 * * page 35, lines 1-8 * * page 62, lines 11-22; claims 17-50 * * page 39, lines 36,37 * * page 40 *;
 [X]  - M. TAKAHASHI, "Inhibition of spontaneous leukemia in F-344 rats by tetramethylthiuram disulfide", GANN, (1983), vol. 74, no. 6, pages 810 - 813, XP002108882 [X] 1-13,20,22-24,31 * the whole document *
 [X]  - G. WEBER, "Neue systemische Therapie der Psoriasis", HAUTARZT, (1985), vol. 36, no. 1, pages 20 - 24, XP002108883 [X] 1-13,22-24 * the whole document *
 [X]  - B.S. WARREN, "Mechanisms of inhibition of tumor progression", BASIC LIFE SCI., (1993), vol. 61, pages 279 - 289, XP002108884 [X] 1-13,20-24,31 * page 285; figure 3; table 2 *
 [X]  - G.Y. LIU, "Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through cordinative modulation of NFkB, c-fos/c-jun, and p53 proteins", MOL. CARCINOGEN., (1988), vol. 22, no. 4, pages 235 - 246, XP002108885 [X] 1-13,20-24,31 * the whole document *

DOI:   http://dx.doi.org/10.1002/(SICI)1098-2744(199808)22:4<235::AID-MC5>3.0.CO;2-I
 [X]  - D.J. STEWART, "Phase I study of the combination of disulfiram with cisplatin", AM. J. CLIN. ONCOL., (1987), vol. 10, no. 6, pages 517 - 519, XP002108886 [X] 1-13,20-24,31 * the whole document *
 [X]  - H.K.A. SCHIRMER, "Disulfiram and tumor inhibition", TRANSACTIONS OF THE AMERICAN ASSOCIATION OF GENITO-URINARY SURGEONS, (1966), vol. 58, pages 63 - 66, XP002108887 [X] 1-13,20-24,31 * the whole document *
 [A]  - G.N. HANNAN, "Regulation of polypeptide synthesis in endothelial cells and hybridoma cells by the copper ionophore disulfiram", CELL. BIOL. INT. REP., (1982), vol. 6, no. 5, pages 423 - 432, XP002108888 [A] 1-39 * the whole document *

DOI:   http://dx.doi.org/10.1016/0309-1651(82)90114-X
Examination   - BOLONTRADE M.F. ET AL, "Angiogenesis is an early event in the development of chemically induced skin tumors", CARCINOGENESIS, OXFORD, (1998), vol. 19, no. 12, pages 2107 - 2113
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.